GlassScriptPhysician profile
Marci Levy Kleinrock
NPI 1851709117
$38,592.03
in general payments reported to CMS, 2019-2025
39 companies · $13K in 2025
The $13K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,461 · 2022: $3,283 · 2023: $15K · 2024: $3,489 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $17K · Food and Beverage: $11K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,200 · Travel and Lodging: $1,237 · Education: $806.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $16,960.00 |
| Food and Beverage | $10,645.63 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,200.00 |
| Travel and Lodging | $1,236.62 |
| Education | $806.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $7,431.44 | 2021-2025 | Bimzelx, Cimzia |
| Arcutis Biotherapeutics, INC. | $6,350.37 | 2023-2024 | Zoryve |
| Abbvie INC. | $4,260.40 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $3,244.62 | 2021-2025 | |
| Incyte Corporation | $2,551.48 | 2021-2025 | Opzelura |
| Solta Medical, A Division of Bausch Health US, LLC | $2,229.76 | 2025 | Clear+Brilliant |
| Sun Pharmaceutical Industries INC. | $1,854.92 | 2021-2025 | Winlevi, Absorica Ld, Odomzo |
| Dermavant Sciences, INC. | $1,517.54 | 2023-2024 | Vtama |
| Janssen Biotech, INC. | $1,483.41 | 2021-2025 | Tremfya, Simponi Aria, Remicade |
| Lilly USA, LLC | $1,064.27 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $857.29 | 2021-2025 | Arazlo, Jublia, Duobrii |
| Regeneron Healthcare Solutions, INC. | $640.83 | 2021-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $615.71 | 2021-2025 | |
| Pfizer INC. | $612.57 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $563.78 | 2021-2024 | Sotyktu |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $409.08 | 2025 | Nemluvio, Aklief |
| Merz North America, INC. | $344.19 | 2022-2025 | |
| Janssen Scientific Affairs, LLC | $281.76 | 2021-2025 | Tremfya |
| Organogenesis INC. | $256.02 | 2021-2022 | |
| Epi Health, LLC | $207.77 | 2021-2022 | |
| Journey Medical Corporation | $206.32 | 2021-2022 | |
| Musculoskeletal Transplant Foundation INC. | $196.17 | 2023 | |
| Vyne Pharmaceuticals INC. | $191.26 | 2021 | |
| Organon LLC | $183.52 | 2025 | Vtama, Hadlima |
| Amgen INC. | $178.77 | 2021-2025 | Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.51 | 2022-2024 | Spevigo, Cyltezo |
| Mayne Pharma Commercial LLC | $113.84 | 2021-2023 | |
| Convatec INC. | $97.41 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $92.00 | 2025 | |
| Almirall LLC | $91.63 | 2021-2025 | Seysara |
| Paratek Pharmaceuticals, INC. | $76.64 | 2024-2025 | Nuzyra |
| Leo Pharma INC. | $52.68 | 2022-2025 | Anzupgo, Adbry |
| Regeneron Pharmaceuticals, INC. | $51.58 | 2023 | Dupixent |
| Allergan, INC. | $34.34 | 2021-2022 | |
| Verrica Pharmaceuticals INC. | $33.76 | 2024 | Ycanth |
| Biofrontera INC. | $31.46 | 2021-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Genentech USA, INC. | $18.99 | 2022 | |
| Botanix Sb INC | $15.77 | 2025 | Sofdra |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marci Kleinrock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.